Replay available

Neurocrine Biosciences (NASDAQ:NBIX) Q4 2021 Earnings Call

Neurocrine Biosciences (NASDAQ:NBIX) Q4 2021 earnings call, held 2022-02-11. Watch the replay and read the transcript on 6ix.

Thu, February 10, 2022 at 7:00 PMendedReplay
Neurocrine Biosciences (NASDAQ:NBIX) Q4 2021 Earnings Call
Company
Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Period
Q4 2021 earnings call
Date
Thu, Feb 10, 2022, 7:00 PM ET
Replay
Watch the replay on this page · 1 h 9 min
Results news release
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022 · Fri, Feb 11, 2022

On 6ix: 6ix.com/event/neurocrine-biosciences-inc-nbix-q4-2021-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Vice President of Investor Relations Thank you, operator. Good morning and thanks for joining us on our fourth quarter and full year 2021 earnings call. Joining me today are Kevin Gorman, our chief executive officer, Matt Abernethy, our chief financial officer, Eiry Roberts, our chief medical officer, Eric Benevich, our chief commercial officer, and Kyle Gano, our chief business development and strategy officer.

0:55 I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After our prepared remarks, we will open the call for your questions. With that, I'll hand the call over to Kevin Gorman.

1:17 Thank you, Todd. Good morning. Today, we want to look back at the challenge in 2021 and the last ones we've made. We will also be looking forward to 2022. A year that we believe will set us up for tremendous growth for the next several years. 2021 was bracketed in Q1 and Q4 by rising infections, office closures, and significant staffing shortages that constrained our efforts. However, we did make progress identifying many new healthcare professional customers and how to effectively work with them in a very challenging and changing environment. Eric will go into this in more detail at a moment. Turning our attention to the future, The guidance that we released this morning is founded on the lower end by a continuing unpredictable epidemic that bends and flows.

2:04 The upper end is less constrained by COVID, anticipates reopening of plants for sufficient staff, and the impact in the second half of the year of an expanded sales force more focused on specific points of care than previously. We believe these internal and external events will allow us to bring advice to many more patients who are needlessly suffering with TB. and we'll lead to significant growth both this year and beyond. We have made a good start in addressing this market and we will now re-accelerate growth. Concurrent with our commercial efforts, we have developed a neuroscience portfolio second to none. We have 12 phase two, phase three programs addressing diseases and disorders in neurology, neuropsychiatry and neuroendocrinology. We acknowledge the historical challenges in developing medicines for these diseases.

2:52 And we have designed this pipeline With multiple compounds, each addressing a different mechanism to treat a specific disease, such as the way we are approaching schizophrenia and the way we're approaching major depression. But the flip side of this, we're developing other compounds where each one of these can address multiple diseases. By attacking diseases from these two fronts, we believe we will be successful in addressing otherwise intractable diseases and disorders. Over the next 18 months, this pipeline will have a number of significant redoubts, and Eiry will go into these in more detail. At this time, I'd like to turn it over to Matt.

3:36 Thanks, Kevin, and good morning. Since we preannounced Q4 aggressive sales in early January, I'm going to focus my remarks on our 2022 sales and operating expense guidance. 2022 Engraza Net Sales Guidance Range is $1.25 to $1.35 billion, reflecting our latest thinking considering current trends, environmental factors, and our ongoing business initiatives. This is our first time providing annual sales guidance, and we aim to be as transparent as possible about our assumptions. Our assumptions fall into a few primary categories. The first relates to the external environment. COVID's impact on our business is clear. As COVID cases go up, psychiatric patient visits decline with a higher mix of visits going virtual.

4:26 This combination directly impacts TB diagnosis and ultimately treatment rates. The good news is that COVID cases are starting to decline and we expect site patient visits to increase throughout 2022, leading to a tailwind for Ingress in the second half of the year. But admittedly, it is difficult to predict how the impact of COVID will transpire. The second bucket relates to the benefits we expect from our commercial initiatives, specifically our direct-to-consumer advertising campaign and Salesforce expansion, which is on track to be fully in place next month. We anticipate these initiatives will help accelerate diagnosis and treatment rates, On the payer front, access and net revenue per script are expected to remain consistent with 2021. We assume sales seasonality to be very similar to previous years with June 1 having the most disruption due to the typical growth to net dynamics and the impact on refill rates due to the reauthorization process.

5:32 Now to our operating expense investments. Our 2022 GAAP operating expense guidance range is $1.1 billion to $1.15 billion, with investments focused on accelerating and growing the growth and advancing our many R&D programs. Our SG&A investments primarily reflect $100 million increased spend in the Salesforce expansion and DTC. In addition, our R&D operating expense reflects advancing 12 mid- to late-stage programs in the clinic and also are recently completed in licensing of an M4 agonist from Tose Hapara. Our strong balance sheet, durable cash flow, and T&L profile allow us flexibility to execute our capital allocation priorities, investing in growing Ingresa and advancing our important clinical programs to discover new, Innovative therapies for people who deserve better. Now, over to Eric Benevich.

6:36 Thank you, Matt. Before I begin, I want to acknowledge our commercial and medical affairs team. Throughout last year's challenging external environment, your unwavering dedication and commitment made a meaningful difference to many thousands of patients who otherwise would have continued to needlessly suffer from TDC. Ingressive Q4 performance marked our third straight quarter of sequential growth during the pandemic era. Total prescriptions grew 8% sequentially and grew 32% versus the prior year. While it was good to see that kind of growth, as Kevin said, we strive to improve while managing through several issues, both in and out of our control. First in Q4, changes to our distribution network were implemented.

7:21 and as anticipated, we saw modest shifts in scripts going from some of our specialty pharmacies to CVS and Walgreens retail outlets. Recall, we expanded the distribution network in order to provide even greater ease of access to the reservoir patients and their healthcare providers. The transferring of prescriptions back and forth across our pharmacy network likely led to delayed prescription bills for some of those patients. Second, while difficult to describe how much of an impact first the Delta variant and then the Omicron variant had on TRX and NRX volume, we know the rise in cases significantly impacted our customers and interfered with patient care. Staff shortages and turnover at offices, clinics, and pharmacies likely contributed to an uptick in cycle time from prescription referral to prescription fill.

8:11 Our persistence and compliance remained strong consistent with prior quarters, helping us to maintain momentum going into the new year. All in all, despite a worsening external environment brought on by the surging Omicron variants, particularly in the second half of Q4, we estimate TD diagnosis rates have now grown to around 25% of the TD population. With over 56,000 total prescriptions in Q4, a record level, Ingresa continues to be the number one most prescribed treatment for tardive dyskinesia. Shifting to this year, we've provided the 2022 guidance range for Ingresa and are now over a month into the year. So what have we seen?

8:56 The external environment is slowly improving, but no one is out of the woods yet. We've been encouraged with early signals and are cautiously optimistic that access to our key customers will trend positively as the external environment continues to improve. Internally, the onboarding effort of our Salesforce expansion is well underway. The newly expanded 350-plus strong Salesforce with dedicated teams across psychiatry, neurology, and long-term care will be fully deployed at the end of this quarter. In addition, we plan to run our ongoing TD Spotlight branded direct-to-consumer campaign throughout 2022. With improving market fundamentals and strong conviction in the commercial investments we are making for Engreza, the stage is set for accelerated growth in 2022 and for years to come.

9:48 For Angensis, while we continue to receive positive feedback from patients and neurologists, you should not expect a great acceleration in 2022 sales, as Angensis remains a non-formulary medication on most Medicare Part D plans. And I should reiterate, Angensis opens doors to neurology practices and gives our team more time with prescribers to highlight both Angensis and Ingressive. Furthermore, we strongly believe that having a dedicated neurology team will benefit both products, especially with movement disorder specialists. So with that, I'll turn the call over now to my colleague, Dr. Irie Roberts, for an update on the pipeline.

10:27 Thank you, Eric, and good morning to everyone on the call. Over the last 12 months, we have made tremendous progress across all of research and development. We have advanced a novel and diverse pipeline of 12 mid- to late-stage clinical programs, each of which has the potential to be a first-in-class or best-in-class medicine. 2021 was in many ways a foundational year for neurocrine R&D, with the stage now set for a year of unprecedented investment and execution to advance this pipeline. With the goal of submitting the supplemental new drug application for Valbenazine Huntington's disease, initiating a phase two study in schizophrenia for NBI568, the selective M4 orthosteric agonist recently acquired through our partnership with Sose Heptareus, and delivering a significant number of registrational and phase two data readouts over the next 24 months.

11:34 I'll spend the balance of my prepared remarks on brief status updates across these pipeline programs, beginning with Valbenazine. In the second half of 2022, we plan to submit the SNDA to the FDA for the treatment of chorea associated with Huntington's disease. We were extremely pleased with the safety and efficacy results achieved in the CONNECT-HD study. These data, together with six-month follow-up data from the CONNECT-HD2 study, form the basis of our SNDA submission. Continuing with valbenazine, we recently initiated registration studies for the adjunctive treatment of schizophrenia and for dyskinetic cerebral palsy.

12:21 We anticipate top-line data from these recently initiated studies in 2023. Moving to NBI-104, the selective T-type calcium channel antagonist, in license from Eidolfia. We expect top-line data from two Phase II studies for NBI-104 this year. Somewhere around mid-year, we anticipate delivering proof-of-concept data in essential tremor. Following that, in the second half of the year, we anticipate completing our ongoing trial in epilepsy with continuous spike and wave during sleep. Based on the review of these data generated for MDI-104, we will determine potential next steps for each of these indications.

13:10 Turning now to MDI-352, the selective NAV1.6 sodium channel inhibitor, in license from Xenon, We have two phase two studies ongoing. The first in FCNAAD, a rare pediatric epileptic encephalopathy, and the second in focal onset seizure in adults, from which we anticipate delivering top-line data in 2023. Drifting gears now to the psychiatry portfolio of access, in license from Takeda Pharmaceuticals, we have initiated phase two studies with all three lead programs including Lubadaxastat in cognitive impairment associated with schizophrenia, NBI 845 for inadequate response in major depressive disorder, and NBI 846 in anhedonia in major depressive disorder.

14:05 Top line data for 845 and 846 are anticipated in 2023. Staying within psychiatry, and the lead muscarinic agonist in our collaboration of Sosiheptarin, NDI568. This molecule is a highly selective orthosteric agonist of N4 with the potential to be a best-in-class molecule against this target. We plan to initiate a Phase II study of N568 in North America for the treatment of schizophrenia this year. And finally, with respect to our neuroendocrinology portfolio, We remain on track to read out top-line data for the registrational studies of chronesophon in both the adult and pediatric patient populations in 2023.

14:53 To close, we have built a strong R&D pipeline that has the potential to dramatically change lives for patients. Our focus now is on the effective delivery of this pipeline, while also continuing to add innovative candidates via internal drug discovery and strategic business development, where we believe those efforts can serve the needs of our patients. I want to thank everyone at Neurocrine, our external partners, clinicians, and patients who support us in our ultimate mission to bring medicines to patients who need better treatment options. I'll now hand the call back to Kevin. Thank you, Kevin.

15:36 Thank you, Eiry. That concludes our prepared remarks, and we are ready to open it up for questions. And at this time, if you would like to ask a question, please press the star and 1 on your touch-tone phone. You may withdraw your question at any time by pressing the pound key. We'll move first to Phil Nadeau with Calum. Please go ahead. Good morning. Thanks for taking our question. A question on essential tremor.

16:07 Can you give us some sense of what would be proof of concept for you and what would warrant further development?

16:13 Thank you. Thanks very much, Bill. Yes, certainly. As you know, we have a proof of concept study ongoing, which is a 28-patient crossover study. We have several endpoints in that study. The primary endpoint actually looks at tremor amplitudes. and is measured by accelerometer. But we also have the Tetris measures in that patient population of moderate to severely impacted tremor patients. I think we'll be looking at the data in totality. Obviously, we'll be interested in seeing a statistically significant difference in the crossover design. But beyond that, we'll be looking at the data in totality, including also a CGI assessment as well. And then with the data in hand, sometime around the middle of this year, we'll be considering our next steps if we're successful in that regard.

17:08 Perfect. Thank you. and we'll move next to Paul Mathis with Duck People. Please go ahead. Great. Thanks so much for taking the question. On your ingressive guidance, I was wondering if you could kind of frame for us at the low, midpoint and high end, how demand growth in those different scenarios compares to what you were seeing before the COVID pandemic. Thanks so much.

17:43 Yeah, thanks, Paul. As you look back before the pandemic, you know, we had a nice growth trajectory of, you know, call it a couple hundred million dollars a year. So when you think about a 20% midpoint growth, you know, it pretty much puts you back on track with how we were going prior to the pandemic. I think the two biggest items that I'd point to as it relates to the guidance range is, one, the environment. As the environment cooperates, patients going back into the office and access to customers is greater. You would expect us to fall higher on the range. If the pandemic continues to have significant pressure, that would, of course, put you closer to the bottom of the range and impacting overall demand. The second piece has been on the business initiative side.

18:34 We're well underway on our sales force expansion that we expect to complete by the end of this quarter, which will benefit us in the second half of the year. And we're optimistic with what we've been seeing recently and with the case counts going down and what we're seeing internally. So we're looking forward to a nice year, another nice growth year for Imbresa. Thank you. And we'll move next to Dazeena Maude from Bank of America. Please go ahead. Hi, good morning, and thank you for taking my questions. Just a point of clarification, is your guidance with or without impact from inventory stocking for Ingresa?

19:24 And then how much of your upper end of guidance is based on the potential for psychiatrists to, you know, continue to be reimbursed for their telephysis at the same level as in person, let's say, for the rest of the year? and if there is a place for Upside, would it be that particular variable or is there something else?

19:45 Thanks. Good morning, Suzanne. I'll take the second part of your question first and that is that within our full range of guidance, we anticipate that there will be no changes to telehealth throughout the entire year.

20:03 Yeah, and that's on the reimbursement front. We, of course, would expect, you know, as the clinics open up from the COVID shutdown, that there would be a higher mix of patient visits in person. But from our reimbursement perspective, our current census is policies likely are not going to be changed this year. On the inventory front, you know, my strong desire is to get rid of talking about the inventory fluctuations quarter to quarter. And, you know, usually within a year it nets out. So, you know, I would say that our guide really reflects underlying demand for in-grade sales. And we'll, of course, be continuing to update our guide at the end of each quarter, which would, you know, take into account any learnings or thinking around that.

20:55 And the only other thing I would add to that is that, you know, to reiterate what Nash said, over a year's period of time, any inventory fluctuations net out. And as we've seen now over multiple quarters, the amount of inventory that's carried on in REVS is actually very small compared to the Fed. Okay. Thank you. And we'll take our next question from Brian Abrams with RBC Capital Markets. Please go ahead. Hey, good morning, guys. Thanks for taking my question, and congrats on all the progress in an otherwise challenging year. A question on commercial investment. It sounds like your investments are going to start to pull through soon.

21:41 from the expanded sales force as the year progresses. I guess I'm curious in medium term as we exit the year, what's the right way to think about the returns that you're hoping to get there? How do the incremental dollars put towards these additional segments you're going to pursue like long-term care translate to revenue compared to the current areas you're in? I'm also curious how much intrinsic growth is left in your current target areas as well beyond just the reopening benefits. Thanks.

22:11 Good morning. So I think the way to think about it is that with the expansion and the reorganization of our field sales team, essentially we're going deeper into existing segments. For example, the build-out of a dedicated neurology team allows us to reach more neurologists and to see them more frequently than we've been able to do thus far in the commercial realm. With the build-out of an LTC team, essentially it's going into a care segment that we were always interested in from the get-go but didn't really have the wherewithal to really put a dedicated focus against. And one way to think about LTC is essentially adjacent to the psychiatry space.

23:03 There are providers that practice in both Thank you for joining us. But at the same time, it's allowing us to go deeper within the existing base of providers. And I think it's really a function of where we are in the commercial ramp for Ingresa. About five years now, and there's certainly more prescribers than what we had in the early phase of the launch, and there's certainly more high-value potential prescribers that we've identified.

23:52 The other thing I would note is this allows us to put a little bit more focus on, you know, what's been an emerging high priority segment of prescribers, which is advanced practice providers, meaning nurse practitioners and physician assistants that go across all of those types of care. So, you know, the way to think about it is, you know, we're going deeper into the existing segments and, you know, we're tapping into a new opportunity in long-term care We'll be providing more insights as we move through the year and get into 2023. Thanks so much. We'll move next to a new palm warmer with J.P.

24:37 Morgan. Please go ahead. Hey, guys. Thanks so much for taking the question. I was wondering if we could dig in a little bit into 1Q dynamics specifically. I think at the conference you talked about 5,300 per script, which is in line with 4Q, but is there any other color you would want to provide on 1Q specifically? I think previously you've given a little bit more color and guidance on 1Q, just kind of worried about numbers going all over the place.

25:09 Yeah, thanks, Anupam. And as you said, Q1 always has some dynamics. The growth in that discount, you have patients going through a reauthorization process that ultimately delays their first fill and results in a lower refill rate per patient during the first quarter. So, yeah, it is always a bit noisy from a seasonality perspective. Typically, you see Q4 to Q1 a bit of a pullback in Q1 because of the net revenue per strip going down. and then also the slight impact on the refill rate per patient. And then you see a nice recovery in Q2 and throughout the year. Since we're providing an annual guide, we're going to get out of some of the specificity that we've historically Thank you. Thank you.

26:22 I'll chime in here and just add that obviously with the surge in the Omicron variant in late Q4 and early Q1, that presented additional challenges for us to deal with. Certainly that affected our customers with a lot of clinics having staff shortages, providers falling ill and so on. It affected a good chunk of our sales team as well, with a number of our team members needing to quarantine. The good news is that things appear to be getting better. We're cautiously optimistic that we're seeing an improving external environment, and certainly that benefits our business.

27:08 And the only thing I would add to that, Anupam, is that The commercial team put a lot of pre-positioned effort in place, starting actually in Q4, in order to help with what we said was looking like it was going to be a very challenging Q1. I think those efforts are going to come to fruition. Like Eric said, I think the best way to put it is we're cautiously optimistic an improving environment can only help. Thanks so much for taking our questions. and we'll move next to Carter Gould with Barclays. Please go ahead. Great. Good morning. Taking the questions.

27:53 Maybe one for Irie. Just as we think about coming back to 104, think about read-through from the essential tremor study to the epilepsy data later in the year. Are there specific data that would come out of the ET study that might have some positive read-through or de-risk? the ET study, and then you guys have always talked about more broadly the potential for additional indications. Are there specific signals from that ET study that might be insightful as you think about future indications?

28:25 Thank you. Yeah, thanks very much. So we know that the calcium channels, that are impacted by 104 are represented within that tremor network, and that that tremor network also links very directly to epilepsy from a mechanistic perspective. So actually, in terms of information that we're able to generate from the ET study, I think it is helpful in understanding the pharmacodynamic effect of medication and some of the dose-related issues in using 104. In addition, obviously, we will get initial tolerability information in a patient population from the ET study that is in some way relevant to our CSWS study because obviously it's a very different population.

29:18 and if you think about CSWS, it's a rare pediatric epileptic encephalopathy and the patients in that study will be aged two upwards and so it is different from the ET population which is significantly older adult population. So I think in general we'll be looking in the totality of both the The efficacy data from the ET program and the initial safety and tolerability. And we won't have to wait very long to understand the actual signal in the CSWS space anyway, since we will be reading out the data from that 24-patient phase 2 study in CSWS in the latter part of the year as well. Move next to Nina Petrito-Gard with Citi. Please go ahead.

30:19 Hey, guys. Thanks for taking my question. Just going back to graduate guidance, I'm just wondering if you can give us a sense of how you're thinking about the proportion of in-person patient visits versus telehealth at the low, midpoint, and high end of the range and whether the CMS decision that you've talked about previously on having patients, seeing psychiatrists, having their first visit in person, and then every year after that, whether that'll be a 2022 or more likely 2023 event. Thanks.

30:53 Yeah, the way that we're thinking about telehealth is that, you know, certainly it impacts different portions of our business differently. You know, ultimately, it's utilized quite a bit, has been utilized quite a bit, and continues to be utilized at a high rate within psychiatry. You know, the latest data that we've seen is that it's still about half of all patient visits are virtual in psychiatry, whereas in neurology, it's less than 10%. Frankly, it's returning to pretty close to what it was pre-COVID. and telehealth is utilized to a much, much lesser degree in LTC, for example. And so, you know, our expectation is that, you know, even after the public health emergency is lifted, that there's going to be a significant utilization of telehealth in psychiatry.

31:48 And, you know, we've baked that into our planning and our assumptions. The second part of your question was really around some of the guardrails that are being proposed, such as having a first visit requirement be in person and at least once a year in-person visits for subsequent telehealth visits to be reimbursed. You know, we're certainly supportive of making sure that... The patients have the opportunity to see their providers in person. We recognize the value that telehealth provides in certain circumstances, but want to make sure that there are guardrails in place going forward. So we'll see how things shake out. But, you know, for the duration of 2022, our expectation is status quo.

32:39 Thank you. And we'll move next to Brian Scorny with Baird. Please go ahead.

32:50 Hi, this is Lou Kerman. I'm for Brian. Thanks for taking our question. Could you just discuss a bit your expectations for how an approval in Korea and Huntington's disease could impact Ingress's growth rate? And do you expect the sequencing of uptake and that indication to be more front-loaded or occur at a gradual pace? Thanks.

33:11 Yeah, so, you know, first of all, I want to emphasize that we need to finish the open label study and get the SMEA submitted. But assuming that we're successful and we get a label expansion in 2023, we're very excited about the opportunity to bring Igreza to a new patient population, those patients with Huntington's that are experienced in Korea. The way to think about it is that it's all incremental to our business. You know, we're not getting any, essentially any of those Huntington patients now. The health plans, you know, because this is a specialty product and it's a prior authorization process, you know, they're approving and ready for TD, but essentially not for other uses.

34:01 So, We're looking forward to the opportunity to expand the label. The second part of your question was really around would this be front-loaded or would this be a more gradual ramp? We can provide a little bit more color when we get further down the road and we have a sense of what the labeling is going to look like. Ultimately, I will say that we view the patient opportunity within Huntington's Korea as a group of patients that have unmet medical needs. Only about 20% of the patients with Huntington's Pria are currently treated with a DMF2 inhibitor. So certainly there's an opportunity for a differentiated product like Ingredza to come in. and, you know, to potentially benefit many thousands more patients with honey in Korea.

34:48 So stay tuned for more as we make progress in pursuing that label extension.

34:54 And the only thing I would add to that is that obviously having a dedicated neurology sales force now with being Greta will help with that. They can, at the time of approval, can start focusing their efforts on treating these cheating patients. Thank you. And we'll move next to Myles Minter with William Blair. Please go ahead.

35:25 Hi. Just back on the channel. What's the new sort of steady state that you'd be expecting moving forward with your growth projections? I think I've heard sort of around the 10 million number be thrown around previously, but that seems to have been creeping over time. So just wondering what the new set point is there for infantry. Thanks.

35:50 Miles, could you clarify your asking about what typical inventory stocking levels would be for... Yeah, and also your projections moving forward with your anticipated growth rates.

36:02 Is that going to change over time? Thanks.

36:05 Yeah, no, I think we'd look at it from a days on hand perspective, which would take into account any of our volume growth. You would typically, in our channel, see two to three weeks of inventory on hand. And as you mentioned, it had grown significantly. from about two weeks to about three weeks, and we're somewhere in between there right now. So, you know, our goal is, you know, we don't influence channel stocking. You know, we really are somewhat hands-off with our distributors. products for a variety of reasons. But I think a two- to three-week days on hand is what you should expect. And it's become, as Kevin said earlier, a less meaningful number quarter to quarter. You know, of course, if there's some major fluctuation, we'll be transparent as always.

37:01 But, you know, as you think about the annual guide, you know it should net out for the most part throughout the year from a days on hand perspective.

37:10 Cool, thanks. And we'll move next to Josh Shimmer with Apricor. Please go ahead. Thanks for taking the questions. Are you planning additional business activities this year, and what is your appetite for larger deals? And then, Matt, you just indicated you're hands-off with distributors with respect to inventory for a variety of reasons. Can you share what some of those reasons are? Thanks.

37:43 Yeah, one of the reasons is just for purposes of causing undue volatility in our sales projections. Or sorry, our sales performance. I think there are some practices that really incentivize stocking, whether giving incremental discounts or whatnot to hit a target number. And we just don't want to be in a place where we're, you know, overly influencing stock. try to talk more towards underlying demand, which is why we've always provided TRX. And I would just say that's one of the primary reasons.

38:28 And discourage speculative buying.

38:33 And as far as business development, I'll turn that over to Kyle Gano on business development.

38:39 Hi, Josh. Good morning. On the BD side of things, just to recap kind of our priorities here at NERF, and obviously we are investing heavily in Greza and Valbenazine and Wally, the DMAT2 franchise, and second to that is the pipeline and business development. So we are still looking and active out there looking to bring things into the pipeline if it makes sense. I think from our mid- to long-term objectives, We continuously assess all types of opportunities ranging from traditional licensing deals and collaborations to things that are more strategic. So if we can find things that make sense and work for us, we'll look at bringing those in. And I think that you've seen that done over the past few years in the pipeline currently with the assets that we have in the late stage of all of that.

39:25 We do not constrain ourselves. Thank you. and we'll take our next question from David Anselm with Piper Sandler. Please go ahead. Thanks. So regarding the long-term care opportunity, you talked about this being a new opportunity and I may have missed this. Can you talk about what portion of the TD market is long-term care based and how you should think about, how we should think about You know, underlying not just volume potential here, but even sales potential to the extent that you can quantify that. Thank you.

40:12 Yeah, we haven't given any guidance specifically around, you know, what the sales expectations are for long-term care. But, you know, the way to think about it is that the way that we think about long-term care is it really represents a few different types of residential care facilities that treat residents or patients with the antipsychotics and dopamine blocking drugs that cause TB. And so that would include, you know, geriatric nursing homes. That might include facilities that treat patients with intellectual or developmental disorders. That would include residential care facilities or assisted living facilities for those with behavioral health conditions. And so, ultimately, you know, if you look at that roll-up, you know, that represents several million people across the U.S. that are in those facilities.

41:17 And at any given time, you could expect somewhere between 15% and 30% of those individuals to to be on antipsychotics and, you know, obviously a subset of them having PD. So, you know, where it shakes out in terms of the size of the addressable patient population with PD in LTC versus the overall PD prevalence population remains to be seen, you know, but we certainly feel like and believe based on the early experience that we have in that space It's a significant incremental opportunity and it's a segment that we are interested in going into early in the launch. But like I said earlier, they wouldn't have the resources and the capacity to focus on it. So I think you'll be getting a lot more color and perspective as we make progress. But I will say that we're just getting our team hired and trained. They'll be deployed as we exit Q1.

42:20 and really for the next couple of quarters, we'll be doing a lot to really better characterize that opportunity and set ourselves up for success as we exit 2022 and get into 2023. Thank you. And take our next question from Jay Olson with Alkenheimer. Please go ahead. Oh, hey, congrats on all the progress, and thank you for this update. Since the total addressable TB market in the U.S. is now 600,000 patients, can you comment on how fast that population is growing? And with the 25% of patients diagnosed, can you talk about your goal for the ultimate level of TB diagnosis as you continue your education and awareness initiatives? Thank you.

43:19 Yeah, so, you know, our estimate is around 600,000 people in the U.S. with tardive dyskinesia, and that's, you know, based on a meta-analysis of the literature as well as looking at claims data, et cetera. And we periodically reassess this. This is a growing population, and it's really a function of the The rapid growth of the use of antipsychotics, especially in Non-psychotic conditions. So if you think about it, antipsychotics are widely used to treat the adjunctive treatments in schizophrenia. They're used in bipolar. They're used to treat anxiety. There's a number of off-label uses of antipsychotics.

44:05 And so, you know, we have seen that over time as the use of antipsychotics expands, unfortunately, so does the population with T.D., We'll continue to reassess the size of the population and, importantly, the progress that we're making in helping those patients get diagnosed. At the beginning of our launch, back in 2017, we estimated no single digit percent of those individuals had yet to be given a diagnosis. Today, we estimate about a quarter of them have been diagnosed. Importantly, only about half of patients that get a diagnosis today are even offered a DMF2 inhibitor. So there's a long way to go in terms of making progress with bridging the gap between the diagnosed population and the prevalent population, as well as making sure that everyone that gets a diagnosis is offered effective treatment.

45:04 The last thing I'll say here is, you know, you asked about what's the goal. Well, the goal would be 100%, but realistically, you know, that not everyone that, you know, gets a disease is going to get diagnosed. But we certainly can get a lot higher in the coming years in terms of making sure that he is routinely screened and diagnosed, regardless of care setting. And we're leveraging the APA guidelines. to really reinforce that that is the expectation and that is the standard of care for especially these patients with psychiatric conditions being treated with antipsychotic medicine. Great. Thank you very much. And we'll move next to Vimal Devon with Mizzou Health Securities.

45:57 Please go ahead. Great. Thanks for taking my question. Maybe one just to follow up on the last question. I think you said it's a growing population. I don't know if maybe you could quantify that a little bit for us. It's kind of how you see the overall TV market growth. But my question is that you're on a pickup phone. And I know there's a lot of synergies for that product and having your reps selling that along with Ingressa. But I'm just curious if you can give us a little better sense when you think you may be able to get better commercial access. and when you think it actually might on its own sort of be delivering more sales. I mean, I'm looking at consensus numbers. It does look like people are assuming a couple hundred million in sales for that product alone, you know, out several years from now. So, I'm just trying to get a sense if you think that's realistic or to think of that as a smaller opportunity that's more the synergies again where we should see the value.

46:46 Thank you.

46:48 Yeah, let me address your, the question of, the clarifying question about the growing population. And then I'll tackle your question about ongenesis. So the reason I said that it's a growing population is that the use of antipsychotics continues to expand. There's been 60 million? Yeah, 70, excuse me. Thank you for joining us. Even though second-generation antipsychotics tend to have a lower incidence of PD, the greatly expanded use of antipsychotics is what's leading to a growing PD patient population over time.

47:51 So that, once again, is something that we continue to monitor and we update our estimates. And, you know, you might recall that five years ago our estimate was around 500,000 people were feeding, and today we estimate it's closer to 600,000.

48:06 So if you correlate 2D prevalence with... The other part of your question was related on Genesis and coverage. I made a point in my prepared remarks that we shouldn't expect a great acceleration

48:46 with the sales of Angensis in 2022, primarily because for the majority of Medicare Part D plans, it remains a non-formulary product. And I will clarify that that is a dynamic that's seen really across all brands of anti-Parkinson's medicines. especially within the Medicare plans that tend to treat branded medicines as non-formulary products. So we'll continue to help our customers to get access through the formulary exceptions process. The other thing I'll say is that we do believe that having a dedicated neurology sales team will benefit on-campus. As I mentioned earlier, allows us to reach more neurologists and to see our highest value customers more frequently.

49:39 And that would benefit both on Gensys and, of course, in part of dyskinesia. Okay, thank you. We'll move next to Mark Goodman with SBC Lyric. Please go ahead.

50:01 Thanks. Eiry, can you talk about why you like the selective M4 agonist? You know, just in the context, we have different companies pursuing, you know, M1 or M1, M4. I'm just curious, you know, why you like this one. And Matt, maybe could you just clarify the comments on the press release just about taxes and just so we understand what will be the, you know, the tax on the income statement versus the actual cash taxes and when these NOLs are going to run off and just how we should think about tax rate going forward. Thank you.

50:31 Yeah, certainly. So, yeah, we're very excited about the opportunity that we have for the selected M4 agonist. And if you're correct, there are two molecules in this space that have at least in part validated clinically the M4 mechanism in the treatment of psychosis and schizophrenia. The reason we like the molecule that we were able to acquire here is that this is a selective Direct Agonist of M4, and that gives us a benefit in several ways. First of all, because it's not an ulceric modulator, which is what one of the competitive models in the space mechanism is, it doesn't require the substrate acetylcholine to be effective in the brain in treating patients, and certainly in many indications, that we might be interested in pursuing with our muscarinic portfolio.

51:30 There is a deficit of acetylcholine in those patient populations, and so the likelihood of having an effective medication that requires the presence of that substrate is in question, I would say. And so with the direct agonist approach, we believe we have the potential to be a best-in-class opportunity against this target. And then we will be starting a clinical study and Faye Chu in schizophrenia to understand that better later this year. Thank you.

52:03 Yeah, so on the tax front, you know, it's always noisy when you have low book income and your permanent items will drive different Thank you for joining us. that causes you to have to capitalize your R&D and that then gets taken as a deduction over time now.

52:48 Hopefully that legislation does change, but I would just say that that's going to cause us to burn through the remainder of our NOLs this year. That then puts us in a position where we're paying federal cash tax here later this year, but it would be I want to guide you to a 4-5% of income cash tax for state and a little bit on the federal side and then next year we'll more than likely be a full cash tax payer that would be somewhat equivalent to our effective tax rate.

53:34 Thanks. And who's next? to Charles Duncan with Cantrip Fitzgerald. Please go ahead. Yeah, good morning, Kevin and team. Congrats on weathering, effectively weathering the challenges of 21. Thanks for the guide. I had two quick questions, one for Eric, one for Eiry. The Eric question is related to the new Salesforce deployment, you said, really in the field this month, but I guess, or by the end of the quarter. But I guess I'm wondering if you could give us a sense of the key metrics beyond revenue that you would look to to gauge that investment. And then for Eiry, I'm wondering about 104, you know, essential tremor versus CSWS, very different patient populations.

54:32 And I guess I'm wondering if You could provide us color on the endpoints that you're looking at for those proof of concept studies and which ones have perhaps more predictive value for clinical success over time.

54:52 Good morning, Chas. With regard to the new sales team members, we are going to be looking at what I'll call leading indicators. as we get out of the gate and certainly looking to learn as we go and make adjustments going into the year. The kind of leading indicators that I'm talking about really are related to how quickly the new team members can become effective in their roles. You know, everyone that we're hiring has considerable experience, either in psychiatry, neurology, long-term care, you know, average of about 15 years of sales experience.

55:41 However, they haven't sold TD medication before. They haven't sold Inbreva. And so, you know, there is a little bit of a learning curve. And so some of the things that we look at include, you know, how able they are to get in front of their key customers, The ability to leverage resources like peer-to-peer programs, sampling, lunchtime in-service programs, things like that. And ultimately, we will be tracking effectiveness in terms of generating new patient starts as a key component. There's been a lot of work that's been happening here as we've been hiring and training our new team members. to help them get off to a new start, you know, warm handoffs of existing customer relationships, doing ride-alongs in the field and so on. So, you know, we're really excited about having an expanded field sales team, and we're very optimistic about the impact it's going to have, especially in the second half of the year.

56:46 So stay tuned for more as we get further into it.

56:50 Okay, so on 104, the first thing I would say is that these are both space tools. Thank you very much. Although they are not the clinical endpoint themselves, they are very helpful and informative with respect to the clinical impact that the medication could likely have. Also, for both the ET trial and the CSWS trial, we do have the clinical endpoints themselves binned into the trial, but obviously these are relatively short-term treatment trials.

57:39 whilst we'll get an indication from these initial Phase II trials as to the clinical impact of the meditations beyond the primary endpoint. I think it would obviously require us to go into larger-scale registration trials to validate that. Very good. Helpful. Thank you. And we'll move next to Chris Shibutani with Goldman Sachs. Please go ahead. Great. Thank you. Two questions. Eiry, if I could press you a little bit further on 104 there, maybe talk about what your expectations are for the placebo response in the essential tremor study. Others have observed very large placebo effects.

58:25 So can you quantify what you think would be the bar to hit in terms of treatment response in terms of either perhaps percentage of patients responding or the percent decrease in tremor amplitude? and then a second question from Matt. Appreciate the first-time annual guidance. If I think back to 2021, granted unusual period, you were helping us with fairly specific guidance on the revenue from a quarterly basis. So, as you have not provided commentary specifically beyond the general seasonality that this experience seems to have, Should we interpret this to mean that you're comfortable with where consensus currently is in terms of thinking about ingressor revenues as we progress in particular for the first quarter?

59:10 Thank you.

59:12 Okay, briefly for the 104 question, I mean, obviously there are two trials. In CSWS, that is an EEG endpoint in a very severely impacted patient population where we would anticipate the placebo response from the EEG to be low, and I think There haven't been studies done to any great extent in that population, but for treatments that have looked at that EEG endpoint, such as steroid treatment, I think the placebo-responsive anticipate there is low. In essential tremor, it's very variable, as you said. We have designed this study in order to try to mitigate against placebo response. It's a single-site study. It's a crossover study which allows us the power to look within a subject. And so I think we have done everything within our power to mitigate that response. And obviously then mid-year, as we get the data, we'll be able to take a look at that and see what we see.

1:00:07 Yeah, as I said earlier, Chris, on the annual guide, you know, we feel comfortable with the ranges that we've provided. And I think when you look back over time, you can see the normal seasonality of bales being at a low 20%. for Q1, which really reflects somewhat of a pullback from Q4 to Q1. And then, like I said earlier, recovery into Q2. I would say the biggest dynamic outside of the environment really comes down to how effective we are at keeping patients on treatment and how quickly they get through that reauthorization process. And as Kevin and Eric mentioned earlier, we are working very hard in Q4 to be on There would be a lot of desire for me to be more specific than what I am on Q1, but I think the dynamics are fairly clear.

1:01:06 Hard to predict, I know. On the growth in that front, just a clarification, and I think Ana Palm had raised this. In Q1, we would expect our net revenue per script to be around, call it $5,300, and then it will improve throughout the year as the growth in that discount wanes coming out of the donut hole. And on average, we would expect our net revenue per script to be around $5,400, which is similar to 2021. Thanks. And we'll move next to Evan Siegerman with BMO Capital Markets. Please go ahead.

1:01:51 Hi, guys. Thank you so much for taking my questions. So this is not the first time you've made a discreet investment in the commercial effort of the organization for Ingresa. Can you remind us what the ROI was on the prior investment?

1:02:03 And what do you hope to drive from this $100 million incremental investment? Are there any specific metrics you're looking at here?

1:02:09 Thank you. Yes. As you've noted, it's not the first investment. And, frankly... It may not be the last as we move forward over the course of what's a very long lifecycle for this product. As a reminder, we launched in 2015 with an initial sales force, excuse me, 2017 with an initial sales force of about 140 territories. I quickly learned that we needed to expand the field sales force because of the rapid update that we were seeing and frankly that exceeded our early expectations.

1:02:55 The team that we've had in place for the last several years has been a little over 200 territories covering both neurology and psychiatry and as we had disclosed previously in looking at where we were with the development of the market the fact that we've made progress in Raising the diagnosis rate, the fact that there are a much larger number of prescribers of Ingressa now than there were early in the launch, and frankly, a large number of high-potential prescribers, we decided to pull the trigger on reorganizing and expanding our field sales team. And, you know, we think that it's the right thing to do in terms of being able to accelerate growth for the brands. Thank you for joining us.

1:04:13 Thank you for joining us. is essentially an untapped opportunity. So I don't know that we'll get down to providing ROI assessments, but certainly we'll provide some additional insight in terms of how are businesses growing and where the sources of business are coming from as we progress in this next phase of growth.

1:04:57 Great. Thank you. And we'll take our last question from Jeff Hung with Morgan Stanley. Please go ahead. Thanks for taking the question and sitting in. For IRE, if I could ask a little bit more on 104. I know you said that you would look at the totality of the data in central tremors and you need to look beyond the primary endpoint, but what kind of change in amplitude at peak frequency of the postural tremor would be clinically meaningful in this patient population?

1:05:28 I'm not interested to be able to answer that. I don't think there's been a direct correlation or enough work done. If you think about this field, there's nothing being approved for the treatment since 1970, and really now the only effective treatment is off-label medications that are used. We're doing this study looking at what we believe is a very well-controlled and appropriate endpoint. to assess the trauma frequency. But in addition to that, we'll obviously be looking at the Tetris ratings, which are the more clinically relevant ratings in that study that include activities of daily living. And so, you know, for this type of proof-of-concept study, I'm really interested in the totality of the data, not to forget the initial tolerability and safety that clearly is going to be critical for a treatment that can be successful in the long run. Thank you.

1:06:17 And since you mentioned the tetras, are there specific changes in tetras or CGIC that would be clinically meaningful?

1:06:25 I mean, this is a 28-patient crossover study with two weeks of dosing for each element of the crossover, and so I think we'll be very pleased if we see anything in that regard, and obviously that sets us up for further discussion for further interactions for registration programs. Thank you. And I would now like to turn the call back to Kevin Gorman for any closing remarks.

1:06:56 Thank you very much, and thank you everyone for your attention this morning. As you've seen and heard today, we have quite a busy year ahead of us. What I'm looking forward to this year is getting aggressive to return to pre-pandemic growth levels. I think that's very important, and I'm confident that we'll be able to do that. I also look at a very robust pipeline with 12 Phase II and Phase III programs. And they're going to yield multiple milestones, both this year and next year. And when we look specifically at this year, we've talked about MBI-104 and yielding data in both essential tremor and CSWS.

1:07:43 We're also looking forward to submitting the Huntington's disease And then finally, we are committed to finishing enrollment both in the adult and in the pediatric P&H studies and then getting the submission ready for those two NDAs. So a busy year, and as I said, the following year is going to be jammed with even more milestones. So once again, I thank you very much for your attention today, and we're really looking forward to getting out and meeting with all of you in person throughout the year. Take care. This does conclude today's program. Thank you for your participation.

1:08:32 You may disconnect at any time. Have a wonderful day.

Follow Neurocrine Biosciences, Inc. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Kevin Gorman

Chief Executive Officer

Matt Abernethy

Chief Financial Officer

Eiry Roberts

Chief Medical Officer

Eric Benevich

Chief Commercial Officer

More from Neurocrine Biosciences, Inc.